| 000 | 03038nam a2200445 i 4500 | ||
|---|---|---|---|
| 999 |
_c362752 _d362752 _x1 |
||
| 001 | 362752 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102121612.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 210428s2021 sz a s |||| 0|eng d | ||
| 020 | _a9783030690328 | ||
| 024 | 7 |
_a10.1007/978-3-030-69032-8 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC392 _b2021 EB |
|
| 245 | 0 | 0 |
_aMonoclonal Antibodies in Headache . _bFrom Bench to Patient _cedited by Antoinette Maassen van den Brink, Paolo Martelletti |
| 250 | _aFirst edition 2021 | ||
| 264 | 1 |
_aCham _bSpringer International Publishing _c2021 |
|
| 264 | 4 | _c2021 | |
| 300 |
_a1 recurso en línea (X, 172 páginas) _b18 ilustraciones a color |
||
| 336 |
_2rdacontent _aTexto _btxt |
||
| 337 |
_2rdamedia _aelectrónico _bc |
||
| 338 |
_2rdacarrier _arecurso electrónico _bcr |
||
| 347 |
_aArchivo de texto _bPDF |
||
| 490 | 0 |
_aHeadache _x2197-6538 |
|
| 505 | 0 | _aThe CGRP family of neuropeptides and their receptors in the trigeminovascular system.-Pharmacology; where do the mAbs act, gepants vs mAbs -- Monoclonal Antibody Biology -- Guidelines for clinical trials -- Human Models -- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders -- Galcanezumab -- Eptinezumab -- Erenumab -- Fremanezumab -- Potential side effects and pregnancy -- Real-world data, clinical practice so far -- Migraine vs Cluster headache and potential other indications. | |
| 520 | _aIntended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students. | ||
| 988 | _aSpringer_Medicine_2021 | ||
| 650 | 7 |
_2embne _9139470 _aCefalalgia |
|
| 700 | 1 |
_aMaassen van den Brink, Antoinette _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 700 | 1 |
_aMartelletti, Paolo _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 776 | 0 | 8 |
_iPrinted edition: _z9783030690311 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030690335 |
| 776 | 0 | 8 |
_iPrinted edition: _z9783030690342 |
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-69032-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b02/2022 _dz _ek _zSI |
||